Clinical Trial Update: PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PMZ-1620 (Sovateltide) in mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• PMZ-1620 (Sovateltide)

Snippet

Sponsor: Pharmazz, Inc. | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: COMPLETED